Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one
2. Ccd 1042
3. Ccd-1042
4. Ztalmy
1. 38398-32-2
2. Ccd 1042
3. Ztalmy
4. Ccd-1042
5. 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one
6. 98wi44ohiq
7. 1-((3r,5s,8r,9s,10s,13s,14s,17s)-3-hydroxy-3,10,13-trimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethanone
8. 1-[(3r,5s,8r,9s,10s,13s,14s,17s)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
9. Pregnan-20-one, 3-hydroxy-3-methyl-, (3a,5a)-
10. Ncgc00165802-02
11. Dsstox_cid_26503
12. Dsstox_rid_81672
13. Dsstox_gsid_46503
14. 1-((3r,5s,8r,9s,10s,13s,14s,17s)-3-hydroxy-3,10,13-trimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethan-1-one
15. Cas-38398-32-2
16. Ganaxolone [usan]
17. Ganaxolone [usan:inn]
18. Unii-98wi44ohiq
19. Ganaxolone, Solid
20. Ganaxolone [mi]
21. Ganaxolone [inn]
22. Ganaxolone (usan/inn)
23. Ganaxolone [who-dd]
24. Schembl144522
25. (3alpha,5alpha)-3-hydroxy-3-methylpregnan-20-one
26. Chembl1568698
27. Dtxsid6046503
28. Gtpl11942
29. Ccd1042
30. Chebi:177658
31. Dea No. 2401
32. Hms3261k19
33. Amy38916
34. Zinc3824281
35. Tox21_112264
36. Tox21_500379
37. Bdbm50369240
38. Mfcd09971088
39. Akos027327586
40. Tox21_112264_1
41. Ccg-221683
42. Db05087
43. Lp00379
44. Sdccgsbi-0633706.p001
45. Ncgc00165802-03
46. Ncgc00261064-01
47. Ncgc00263545-01
48. As-35253
49. B7092
50. (3?,5?)-3-hydroxy-3-methyl-pregnan-20-one
51. 3alpha-hydroxy-3-methyl-5alpha-pregnan-20-one
52. D04300
53. A901692
54. (3alpha,5alpha)-3-hydroxy-3-methyl-pregnan-20-one
55. Q3758034
56. 3.alpha.-hydroxy-3-methyl-5.alpha.-pregnan-20-one
57. Pregnan-20-one, 3-hydroxy-3-methyl-, (3alpha,5alpha)-
58. Pregnan-20-one, 3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)-
59. 1-[(3r,5s,8r,9s,10s,13s,14s,17s)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone.
Molecular Weight | 332.5 g/mol |
---|---|
Molecular Formula | C22H36O2 |
XLogP3 | 5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 1 |
Exact Mass | 332.271530387 g/mol |
Monoisotopic Mass | 332.271530387 g/mol |
Topological Polar Surface Area | 37.3 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 542 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in pediatric indications and seizure disorders.
Treatment of cyclin-dependent kinase-like 5 deficiency disorder
Ganaxolone is a powerful positive allosteric modulator of GABAA receptors with potency and efficacy comparable to its endogenous analog 3a,5a-P (Carter et al., 1997). As with 3a,5a-P, Ganaxolone potentiation of the GABAA receptor occurs at a site distinct from the benzodiazepine site. Ganaxolone has protective activity in diverse rodent seizure models, including clonic seizures induced by pentylenetetrazol (PTZ) and bicuculline (BIC), limbic seizures in the 6 Hz model, and amygdala kindled seizures (Carter et al., 1997; Rogawski and Reddy, 2004; Kaminski et al., 2004).
GABA Modulators
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)
Neurosteroids
Endogenous compounds or drugs that affect neuronal excitability through modulation of specific ionotropic receptors (e.g., GABA-A RECEPTORS). Endogenous neurosteroids are steroid hormones de novo synthesized by neurons and glial cells from steroid metabolite precursors (e.g., PREGNENOLONE). (See all compounds classified as Neurosteroids.)
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AX - Other antiepileptics
N03AX27 - Ganaxolone
1.3-1.9 hours
Ganaxolone belongs to a novel class of neuroactive steroids called epalons, which specifically modulate the -aminobutyric acid type A (GABAA) receptor in the central nervous system (CNS). Chemically related to progesterone but devoid of any hormonal activity, the epalons have potent antiepileptic, anxiolytic, sedative, and hypnotic activities in animals.
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
53
PharmaCompass offers a list of Ganaxolone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ganaxolone manufacturer or Ganaxolone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ganaxolone manufacturer or Ganaxolone supplier.
PharmaCompass also assists you with knowing the Ganaxolone API Price utilized in the formulation of products. Ganaxolone API Price is not always fixed or binding as the Ganaxolone Price is obtained through a variety of data sources. The Ganaxolone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ganaxolone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ganaxolone, including repackagers and relabelers. The FDA regulates Ganaxolone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ganaxolone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ganaxolone manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ganaxolone supplier is an individual or a company that provides Ganaxolone active pharmaceutical ingredient (API) or Ganaxolone finished formulations upon request. The Ganaxolone suppliers may include Ganaxolone API manufacturers, exporters, distributors and traders.
click here to find a list of Ganaxolone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ganaxolone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ganaxolone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ganaxolone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ganaxolone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ganaxolone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ganaxolone suppliers with NDC on PharmaCompass.
Ganaxolone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ganaxolone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ganaxolone GMP manufacturer or Ganaxolone GMP API supplier for your needs.
A Ganaxolone CoA (Certificate of Analysis) is a formal document that attests to Ganaxolone's compliance with Ganaxolone specifications and serves as a tool for batch-level quality control.
Ganaxolone CoA mostly includes findings from lab analyses of a specific batch. For each Ganaxolone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ganaxolone may be tested according to a variety of international standards, such as European Pharmacopoeia (Ganaxolone EP), Ganaxolone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ganaxolone USP).